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Advanced glycation end product (AGE)-mediated
modification of proteins is enhanced both in the kidneys
and aortas of diabetic and uremic patients. However, AGE
modification of deoxyribonucleic acid (DNA) has not
yet been reported in these patients. We performed
immunohistochemistry of kidneys and aortas using a
monoclonal antibody against N2-carboxyethyl-20-
deoxyguanosine (CEdG), a marker of AGE-linked DNA. A total
of 20 kidneys and 20 aortas were obtained by autopsy.
The kidney samples consisted of two groups: nondiabetic
nonkidney disease (control) and diabetic nephropathy. The
aorta samples consisted of four groups: nondiabetic
nonkidney disease (control), diabetes, hemodialysis, and
diabetic hemodialysis. In the kidneys CEdG was detected
predominantly in the nuclei of epithelial cells, mesangial
cells, and endothelial cells of the glomeruli, parietal
epithelial cells, and tubular cells. The number of
CEdG-positive cells in the glomeruli was significantly
increased in diabetic nephropathy compared with control.
In the aortic walls, CEdG was detected predominantly in the
nuclei of macrophages and myofibroblasts. The number
of CEdG-positive cells in the aorta was significantly increased
in hemodialysis patients and diabetic hemodialysis
patients compared with control. The highest number of
CEdG-positive cells in the aorta was observed in diabetic
hemodialysis patients. In conclusion, AGE-mediated
modification of DNA is enhanced in the kidney of diabetic
nephropathy and the aorta of uremic atherosclerosis, and
may induce a loss of genetic integrity in these diseases.
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In the Maillard reaction, free amino groups of proteins react
with reducing sugars (e.g. glucose) and sugar degradation
products (e.g. glyoxal, methylglyoxal, 3-deoxyglucosone) to
form advanced glycation end products (AGEs). The accu-
mulation of AGEs in tissues plays an important role in the
pathogenesis of diabetic nephropathy, chronic renal failure,
atherosclerosis, cataract, Alzheimer’s disease, and rheumatoid
arthritis.1–8 AGEs are formed by modification of lysine and
arginine residues of proteins with glucose. Protein glycation
end products such as Ne-(carboxymethyl)lysine (CML),
pentosidine, and imidazolone are accumulated in the kidneys
and aortas of diabetic and nondiabetic uremic patients.9–17
These findings suggest that AGE modification of protein is
one of the pathogenetic factors contributing to the progres-
sion of diabetic kidney damage and uremic vascular injury.
Recently, it has been reported that AGEs are also formed
by modification of free nucleosides with reducing sugars such
as glucose.18–21 Genomic damage in peripheral lymphocytes,
possibly induced by deoxyribonucleic acid (DNA) glycation,
is enhanced in uremic patients.22,23 However, DNA glycation
products have not yet been demonstrated to be present in
human tissues, and their role has yet to be understood in the
pathogenesis of kidney disease and uremic vascular injury.
N2-carboxyethyl-20-deoxyguanosine (CEdG) was identified
as a major product found in the reaction mixtures of
20-deoxyguanosine and glucose in vitro, and can be used as a
marker of advanced glycation of DNA.19–21 This study aimed
to investigate the role of CEdG in the pathogenesis of diabetic
nephropathy and uremic vascular complications by using
immunohistochemical detection.
RESULTS
Immunohistochemical detection of CEdG in kidneys
Figure 1 shows the chemical structure of CEdG non-
enzymatically formed by the reaction of D-glucose with
20-deoxyguanosine. CEdG was detected predominantly in the
nuclei of epithelial cells, mesangial cells, and endothelial cells
of the glomeruli, parietal epithelial cells, and tubular cells in
the kidneys of diabetic nephropathy (Figure 2a–d). However,
the presence of CEdG-positive nuclei was not so prominent
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in the kidneys of nondiabetic nonkidney disease (control)
(Figure 2e–h) as compared with diabetic nephropathy. The
cells with brown nuclei in the glomeruli were counted as
CEdG-positive, and the cells with blue nuclei were considered
to be CEdG-negative. The numbers of CEdG-positive cells
per glomerulus were 58.075.2 in control and 84.473.5 in
diabetic nephropathy (mean7s.e., n¼ 10, respectively;
Figure 3). The number of CEdG-positive cells per glomerulus
in diabetic nephropathy was significantly increased as
compared with control (Po0.001).
Immunohistochemical detection of CEdG in aortic walls
CEdG was also detected in the cell nuclei of aortic walls
(Figure 4). Most CEdG cells were cluster of differentiation
(CD)-68 positive or smooth muscle actin positive, indicating
that the CEdG-positive cells consisted of macrophages and
myofibroblasts. The CD-31-positive endothelial cells were
detected in the control aorta, but hardly in the diabetic
hemodialysis patients. Thus, the endothelial damage was
observed in the aorta of diabetic hemodialysis patients. The
numbers of CEdG-positive cells in the aortic walls were
109.075.1 in control, 171.4747.3 in diabetes mellitus,
271.6750.2 in hemodialysis patients, and 328.2763.0 in
diabetic hemodialysis patients (mean7s.e., n¼ 5, respec-
tively; Figure 5). The number of CEdG-positive cells in the
aorta was significantly increased in both hemodialysis
patients and diabetic hemodialysis patients as compared
with control (Po0.01).
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Figure 1 | Nonenzymatic formation of CEdG by reaction of D-glucose with 20-deoxyguanosine.
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Figure 2 | Immunostaining of CEdG in the kidneys. Diabetic nephropathy: (a, b) glomerulus in a 66-year-old man with serum creatinine
5.5 mg/dl (original magnifications: a,  100; b,  250); (c, d) tubules in a 53-year-old man with serum creatinine 2.1 mg/dl (original
magnifications: c,  100; d,  250). Control: (e, f) glomerulus in a 68-year-old nonkidney disease man with serum creatinine of 0.5 mg/dl
(original magnifications: e,  100; f,  250); (g, h) tubules in a 43-year-old nonkidney disease man with serum creatinine 0.3 mg/dl (original
magnifications: g,  100; h,  250).
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Figure 3 | Number of CEdG-positive cells in the glomeruli of
patients with nondiabetic nonkidney disease (control) and
diabetic nephropathy (DN). Data are expressed as mean7s.e.
(n¼ 10).
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DISCUSSION
AGE modification of proteins is well known to be involved in
the development of diabetic glomerulosclerosis and uremic
atherosclerosis with or without diabetes. AGEs cause protein
crosslinking, modulate the expression of growth factors and
cytokines, and consequently induce pathogenic changes in
kidney tissues.6,7 The accumulation of AGEs particularly at
sites of atherosclerotic lesions in coronary artery provides a
common mechanism for the high restenosis rates in patients
with diabetes and renal failure by upregulating extracellular
matrix production.9 Much of current research is focused on
the pathogenic role of protein glycation end products, such as
CML, pentosidine, and imidazolone. CML is a major AGE in
renal basement membranes in diabetic nephropathy, and its
accumulation involves upregulation of the receptor for AGE
on glomerular epithelial cells.10 Elevated serum levels of
fluorescent AGE and CML as well as decreased urinary
excretion of CML are found in diabetic patients with renal
impairment.11 CML is localized in the mesangial area, and
pentosidine is localized in glomerular basement membrane in
diabetic retinopathy, while their expression is significantly
correlated with the index of diabetic glomerulosclerosis.12
The association between pentosidine and arteriosclerosis is
found in patients receiving hemodialysis.13 Accumulation of
CML in the aorta is enhanced by chronic renal failure, and
may be involved in the accelerated development of athero-
sclerotic lesions in patients with end-stage renal disease.14 We
found that high levels of imidazolone in kidneys and aortas
of diabetic patients implicate its role in diabetic complica-
tions such as nephropathy and atherosclerosis.15 Thus, there
is no doubt as to the important role of protein-linked AGEs
in renal and vascular lesion.
AGEs are also formed by nucleoside glycation.18–20 N2-
carboxyethyl-guanosine (CEG) is identified as an AGE of
guanosine.18 A competitive enzyme-linked immunosorbant
assay to detect CEG was established by using polyclonal anti-
CEG antiserum.20 CEdG is identified as an AGE of
20-deoxyguanosine.19 Recently, a new monoclonal antibody,
which binds with high affinity and specificity to CEdG, has
been used to measure AGE-modified nucleosides in normal
human urine.21 Nucleotide glycation leads to DNA lesions,
including depurination, single-strand breaks, and mutations
such as insertions, deletions, and transposition.24–30 As a
consequence, DNA glycation could contribute to the well-
established loss of genomic integrity that occurs during
aging, and may induce aging-related complications.31
Increased incidence of cancer at various sites is observed
in dialysis patients.32,33 In particular, cancers of the kidney,
bladder, liver, thyroid, tongue, and uterus cervix, and
multiple myeloma show an enhanced prevalence in dialysis
patients compared with the general population. Impaired
function of the immune system and of DNA repair
mechanisms, as well as reduced antioxidant defense, and
accumulation of carcinogenic compounds due to reduced
renal elimination are found more frequently in dialysis
patients compared with the general population, and may act
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Figure 4 | Immunostaining of CEdG, CD-68, a-SMA, and CD-31 in the aortic walls. (a–d) Diabetic hemodialysis (a 50-year-old man diagnosed
with diabetic mellitus 18 years ago and treated on hemodialysis for 4 years); immunostaining with antibodies against (a) CEdG, (b) CD-68,
(c) a-SMA, and (d) CD-31 (original magnification  100). (e–h) Control (a 71-year-old nondiabetic nonhemodialysis woman); immunostaining
with antibodies against (e) CEdG, (f) CD-68, (g) a-SMA, and (h) CD-31 (original magnification  100).
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Figure 5 | Number of CEdG-positive cells in aortic walls of
patients with nondiabetic nonhemodialysis (control), diabetes
mellitus (DM), hemodialysis (HD), and diabetic hemodialysis
(DMþHD). Data are expressed as mean7s.e. (n¼ 5).
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in concert to accelerate malignant transformation and tumor
formation. AGE modification of DNA may be one of the
causes for increased incidence of cancer in dialysis patients.
The present study was the first to demonstrate an
increased accumulation of CEdG in the kidneys of diabetic
patients and the aortas of hemodialysis patients. The number
of CEdG-positive cells in glomeruli was significantly
increased in diabetic nephropathy. The number of CEdG-
positive cells in aorta walls was significantly increased in
hemodialysis patients with or without diabetes. These results
suggest that CEdG, a DNA-linked AGE, may lead to a loss of
genetic integrity in the kidney of diabetic nephropathy and
the aorta of uremic atherosclerosis.
MATERIALS AND METHODS
Subjects
A total of 20 kidneys and 20 aortas were obtained by autopsy
without any selection criteria, except the following disease
classification. The kidney samples consisted of two groups (10
each): nondiabetic nonkidney disease (control) and diabetic
nephropathy. The aorta samples consisted of four groups (five
each): nondiabetic nonhemodialysis (control), diabetes, hemodia-
lysis, and diabetic hemodialysis. Table 1 shows the characteristics of
the patients. A control patient for a kidney sample with serum
creatinine of 0.1 mg/dl suffered from paralysis of lower extremities
due to malignant lymphoma in the lumbar spine. Another control
patient for an aorta sample with serum creatinine of 0.2 mg/dl
suffered from spinocerebellar degeneration. These bedridden
patients who suffered from severe muscle atrophy showed low levels
of serum creatinine.
The place of sampling of the aorta was abdominal aorta with or
without atherosclerotic lesions just above the branching of renal
arteries. Atherosclerotic lesions were composed of diffuse intimal
thickening, fatty streaks, and/or atherosclerotic plaques. The
atherosclerotic lesions were observed not only in diabetes,
hemodialysis, and diabetic hemodialysis patients, but also in control
patients. However, the extent of atherosclerotic lesions in the control
patients was not so prominent as compared with the other groups.
The causes of death in the patients for kidney samples were as
follows: (1) control: pancreas cancer, hepatocellular carcinoma,
rupture of abdominal aorta aneurism, bile duct cancer, lung cancer,
malignant lymphoma (n¼ 3), tongue cancer, and chronic myelo-
cytic leukemia, (2) diabetic nephropathy: congestive heart failure,
gingiva cancer, respiratory failure, gall bladder cancer, esophageal
cancer, acute myocardial infarction, interstitial pneumonitis,
hemochromatosis, and hepatocellular carcinoma (n¼ 2).
The causes of death in the patients for aorta samples were as
follows: (1) control: sepsis, pneumonia, duodenum cancer (n¼ 2),
and malnutrition, (2) diabetes: hepatic failure, amyotrophic lateral
sclerosis (N¼ 2), hepatocellular carcinoma, and acute myocardial
infarction, (3) hemodialysis: gastrointestinal bleeding, hemorrhage
shock, hypercalcemia, acute myocardial infarction, and colon cancer,
(4) diabetic hemodialysis: sepsis, hydrothorax (n¼ 2), sudden death,
and congestive cardiac failure.
Antibodies
A monoclonal anti-CEdG antibody (MAb M-5.1.6) produced by M
Pischetsrieder recognizes two diastereometers of CedG A,B with
high affinity and specificity.21 The IC50 value of the antibody for
CEdG A,B was 2.1 ng/ml, whereas the other modified nuclueobases
and AGE proteins showed negligible crossreactivity.
A peroxidase-labeled monoclonal anti-CD68 antibody, a perox-
idase-labeled monoclonal anti-a-smooth muscle actin (SMA) anti-
body, and a peroxidase-labeled monoclonal anti-CD31 antibody were
obtained from DAKO (Glostrup, Denmark). A biotin-labeled rabbit
anti-mouse antibody was obtained from Nichirei (Tokyo, Japan).
Immunohistochemistry
CEdG in tissues was detected by indirect immunostaining.
Formalin-fixed and paraffin-embedded kidney and aorta were
cut into 3-mm thick sections and mounted on silane-coated
slides. The sections were dewaxed and dehydrated. Antigen retrieval
was performed by microwave in 0.01 M citrate buffer (pH 6.0)
for 5 min at 600W twice. After being washed in PBS (pH
7.4, 5 min, three times), the sections were treated with 0.3% H2O2
in methanol for 10 min to block endogenous peroxidase activity,
and then blocked with 10% rabbit serum (Nichirei, Tokyo, Japan)
for 30 min at room temperature. Followed by washing in PBS
(5 min, three times), slices were incubated with monoclonal anti-
CEdG antibody (2.5 mg/ml dissolved in 3% BSA/PBS) at 41C
overnight. The slides were incubated with the second antibody
(biotin-labeled rabbit-anti-mouse antibody) at room temperature
for 30 min, and then with peroxidase-conjugated streptavidin
(Nichirei, Tokyo, Japan) at 371C for 30 min. After another wash
with PBS, peroxidase activity was detected by reaction with 3,30-
diaminobenzidine tetrahydrochloride (DAB tablet, Merck KGaA,
Germany, 30 mg/ml, containing 0.03% H2O2) as the chromogen.
Finally, sections were counterstained by 1% methylene green,
dehydrated, and mounted.
Table 1 | Characteristics of patients
Group
Sex
(female/male)
Age mean7s.d.
(min–max) (y)
Duration on HD
mean7s.d. (min–max) (y)
DM history mean7s.d.
(min–max) (y)
Serum creatinine mean7s.d.
(min–max) (mg/dl)
Kidney
Control 2/8 56.9716.4 (22–75) — — 0.570.2 (0.1–0.8)
DN 2/8 66.678.8 (53–79) — 25.479.9 (10–37) 3.671.7 (2.1–6.1)
Aorta
Control 2/3 69.675.1 (62–74) — — 0.870.6 (0.2–1.6)
DM 2/3 71.877.9 (64–85) — 13.279.0 (3–25) 1.270.6 (0.5–2.2)
HD 3/2 69.873.8 (66–76) 15.878.1 (4–24) — 7.073.0 (3.8–10.3)
HD+DM 0/5 64.6717.9 (50–90) 3.072.0 (0.08–5) 19.275.7 (10–25) 6.572.9 (3.6–10.2)
DN: diabetic nephropathy, DM: diabetes mellitus, HD: hemodialysis.
Kidney International (2006) 69, 388–392 391
H Li et al.: CEdG in kidneys and aortas o r i g i n a l a r t i c l e
Aorta tissues were additionally stained in serial sections with a
monoclonal anti-CD68 antibody and a monoclonal anti-SMA
antibody to identify cells increased in tissues, either macrophages
or myofibroblasts, respectively. To ensure the localization of
endothelial cells, a monoclonal anti-CD31 antibody was also used.
All the sections were examined under light microscopy (Nikon
E600), and their pictures were taken with a digital net camera
(Nikon DN100). CEdG-positive cells were counted in 10 glomeruli,
and in 10 1-mm-length areas within the intimal layer of aorta.
Statistics
The data are given as mean7s.e. Statistical analysis was performed
using unpaired t-test for the comparison between two groups in
kidney samples, and analysis of variance for the comparison between
four groups in aorta samples. When there was significant difference
by analysis of variance, Fisher’s protected least significant difference
test was used for further analysis between groups. A P-value less than
0.05 was considered significant.
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